Company / R&D Expense
AtriCure, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$99.2M
FY2025
5-year range
$48.5M / $99.2M
FY2021-FY2025
Trend
+3.2%
vs FY2024
Sector context
#55 of 105
Health Care
What the data says
At $99M, AtriCure, Inc.'s r&d expense ranks #55 of 105 in the Health Care sector. R&D Expense has increased for 8 consecutive years, from $34M in FY2017 to $99M in FY2025.
Based on SEC 10-K filings.
$99M in FY2025 with a 5-year CAGR of +18.2%.
Improved from $74M to $99M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +20.1%
- 5-Year CAGR
- +18.2%
- 10-Year CAGR
- -
Sector benchmark
#55 of 105 in Health CareTop 52% of 105This company $99.2M Sector average $284.2M
▼
-65.1% below sector average
Key checks
Key Insights
- AtriCure, Inc.'s r&d expense has grown for 8 consecutive years.
- 5-year CAGR of +18.2%, indicating consistent growth.
- In FY2025, r&d expense increased 3.2% year-over-year.
- Ranks #55 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Negative profit margin: -9.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $99.2M | +3.2% |
| FY2024 | $96.2M | +30.1% |
| FY2023 | $73.9M | +28.9% |
| FY2022 | $57.3M | +18.2% |
| FY2021 | $48.5M | +12.6% |
| FY2020 | $43.1M | +4.5% |
| FY2019 | $41.2M | +18.7% |
| FY2018 | $34.7M | +1.7% |
| FY2017 | $34.1M | -4.7% |
| FY2016 | $35.8M | +39.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026